English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

We found that the ubiquitin-conjugating enzyme E2-EPF mRNA is highly expressedin cervical squamous cancer relative to normal tissues and its expression levelspositively correlate with clinical stage. Reduction of E2-EPF protein levels by&gt;80% using shRNA decreases the expression levels of HIF-1α, and the proliferation,invasion and tumorigenicity of SiHa, a cervical squamous cancer cell line. E2-EPFknockdown also increases the chemosensitivity to topoisomerase I inhibitor (topotecan)and II (etoposide and doxorubicin). Our results suggest that E2-EPF is associatedwith the growth and aggressivity of cervical tumor cells. Targeting the E2-EPFpathway may have potential clinical applications for the treatment of cervicalcancer.

The ubiquitin-conjugating enzyme E2-EPF is overexpressed in cervical cancer and associates with tumor growth